Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Short term Debt (2022 - 2023)

TriSalus Life Sciences' Short term Debt history spans 2 years, with the latest figure at $10.0 million for Q2 2023.

  • For Q2 2023, Short term Debt changed N/A year-over-year to $10.0 million; the TTM value through Jun 2023 reached $10.0 million, changed N/A, while the annual FY2022 figure was $15.8 million, N/A changed from the prior year.
  • Short term Debt reached $10.0 million in Q2 2023 per TLSIW's latest filing, up from $4.7 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $15.8 million in Q4 2022 to a low of $4.7 million in Q1 2023.